MA37525A1 - Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine - Google Patents
Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodineInfo
- Publication number
- MA37525A1 MA37525A1 MA37525A MA37525A MA37525A1 MA 37525 A1 MA37525 A1 MA 37525A1 MA 37525 A MA37525 A MA 37525A MA 37525 A MA37525 A MA 37525A MA 37525 A1 MA37525 A1 MA 37525A1
- Authority
- MA
- Morocco
- Prior art keywords
- agents
- treatment
- disorders involving
- ryanodine receptors
- involving modulation
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D281/00—Heterocyclic compounds containing rings of more than six members having one nitrogen atom and one sulfur atom as the only ring hetero atoms
- C07D281/02—Seven-membered rings
- C07D281/04—Seven-membered rings having the hetero atoms in positions 1 and 4
- C07D281/08—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems
- C07D281/10—Seven-membered rings having the hetero atoms in positions 1 and 4 condensed with carbocyclic rings or ring systems condensed with one six-membered ring
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
- A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C57/00—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms
- C07C57/02—Unsaturated compounds having carboxyl groups bound to acyclic carbon atoms with only carbon-to-carbon double bonds as unsaturation
- C07C57/13—Dicarboxylic acids
- C07C57/15—Fumaric acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
- C07D285/36—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/10—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing aromatic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/554—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having at least one nitrogen and one sulfur as ring hetero atoms, e.g. clothiapine, diltiazem
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
- Y10S—TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y10S530/00—Chemistry: natural resins or derivatives; peptides or proteins; lignins or reaction products thereof
- Y10S530/827—Proteins from mammals or birds
- Y10S530/841—Muscles; heart
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Epidemiology (AREA)
- Immunology (AREA)
- Physical Education & Sports Medicine (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Urology & Nephrology (AREA)
- Molecular Biology (AREA)
- Diabetes (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Hospice & Palliative Care (AREA)
- Psychiatry (AREA)
- Psychology (AREA)
- Emergency Medicine (AREA)
- Endocrinology (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Obesity (AREA)
- Pulmonology (AREA)
- Transplantation (AREA)
- Vascular Medicine (AREA)
Abstract
La présente invention concerne des dérivés 1,4-benzothiazépines et leur utilisation pour traiter des états, des troubles et des maladies associés à des récepteurs de ryanodine (ryrs) qui régulent la fonction des canaux calciques dans les cellules. L'invention concerne également des compositions pharmaceutiques comprenant les composés et leurs utilisations pour traiter des maladies et des états associés à ryrs, en particulier des troubles cardiaques, musculo-squelettiques et du système nerveux central (snc).
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP12167732.2A EP2708535A1 (fr) | 2012-05-11 | 2012-05-11 | Agents pour le traitement de troubles impliquant la modulation de récepteurs de la ryanodine |
| PCT/EP2013/057958 WO2013156505A1 (fr) | 2012-04-18 | 2013-04-17 | Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| MA37525A1 true MA37525A1 (fr) | 2016-05-31 |
| MA37525B1 MA37525B1 (fr) | 2016-12-30 |
Family
ID=49165460
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MA37525A MA37525B1 (fr) | 2012-05-11 | 2014-11-13 | Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine |
Country Status (48)
Families Citing this family (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2014144654A1 (fr) | 2013-03-15 | 2014-09-18 | Rosalind Franklin University Of Medicine And Science | Composés pour stabiliser des récepteurs de ryanodine à partir de niveaux aberrants de libération de calcium |
| US9725429B2 (en) | 2013-03-15 | 2017-08-08 | Rosalind Franklin University Of Medicine And Science | Furanyl-imine and thiofuranyl-imine compounds for stabilizing ryanodine receptors from aberrant levels of calcium release |
| EP4082538B1 (fr) | 2013-07-18 | 2024-02-14 | Baylor College of Medicine | Procédés et compositions pour le traitement de l'atrophie musculaire, de la faiblesse musculaire, et/ou de la cachexie |
| WO2015197562A1 (fr) * | 2014-06-23 | 2015-12-30 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Méthodes et compositions pharmaceutiques pour le traitement de troubles ou de maladies associées au dysfonctionnement du récepteur de la ryanodine |
| KR102091211B1 (ko) | 2014-07-30 | 2020-03-19 | 가부시키가이샤 아에타스 파루마 | 1,4-벤조티아제핀-1-옥사이드 유도체의 광학 이성질체, 및 그것을 사용한 의약 조성물 |
| US20160207893A1 (en) * | 2014-12-30 | 2016-07-21 | Myotherix, Inc. | Novel calcium modulators |
| ES2643856B1 (es) * | 2016-05-24 | 2018-08-03 | Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea | Triazoles para la regulación de la homeostasis de calcio intracelular |
| WO2018165171A1 (fr) | 2017-03-06 | 2018-09-13 | Washington University | Traitement du syndrome de wolfram et d'autres troubles de stress du réticulum endoplasmique |
| JP7282332B2 (ja) * | 2017-10-25 | 2023-05-29 | 学校法人順天堂 | リアノジン受容体阻害薬 |
| US11026905B2 (en) | 2018-04-19 | 2021-06-08 | Tvardi Therapeutics, Inc. | STAT3 inhibitors |
| BR112020021329A2 (pt) | 2018-04-19 | 2021-04-27 | Tvardi Therapeutics, Inc. | inibidores de stat3 |
| KR20220131947A (ko) | 2020-01-24 | 2022-09-29 | 트발디 테라퓨틱스, 인크. | 치료 화합물, 제제 및 이의 용도 |
| US11981644B2 (en) | 2020-11-06 | 2024-05-14 | Cytokinetics, Inc. | Bicyclic 1,4-diazepanones and therapeutic uses thereof |
| KR20230129267A (ko) | 2021-01-08 | 2023-09-07 | 암고 파마, 인크. | 리아노딘 수용체 조정제의 결정질 형태 및 그의 용도 |
| CN115369163A (zh) * | 2021-05-17 | 2022-11-22 | 中国科学院上海营养与健康研究所 | Ryr2及其下调剂在治疗转移性结直肠癌中的应用 |
| WO2022246114A2 (fr) * | 2021-05-20 | 2022-11-24 | Armgo Pharma, Inc. | Compositions pharmaceutiques comprenant un modulateur du récepteur de la ryanodine et leurs utilisations |
| MX2023013744A (es) * | 2021-05-20 | 2023-12-04 | Armgo Pharma Inc | Composiciones farmaceuticas que comprenden un modulador del receptor de rianodina y sus usos. |
| JP2024539735A (ja) * | 2021-11-16 | 2024-10-29 | アームゴ・ファーマ・インコーポレーテッド | 治療用化合物 |
| US20230302013A1 (en) * | 2022-02-09 | 2023-09-28 | The Trustees Of Columbia University In The City Of New York | METHOD OF TREATING VIRAL-INDUCED COGNITIVE DYSFUNCTION BY TARGETING LEAKY RyR2 CHANNELS |
| EP4230196A1 (fr) | 2022-02-21 | 2023-08-23 | Som Innovation Biotech, S.A. | Composés à utiliser dans le traitement des dystrophinopathies |
| CA3254067A1 (fr) | 2022-06-15 | 2023-12-21 | Tvardi Therapeutics, Inc. | Promédicaments d'inhibiteurs de stat3 |
| EP4548971A1 (fr) * | 2023-11-06 | 2025-05-07 | Georg-August-Universität Göttingen Stiftung Öffentlichen Rechts, Universitätsmedizin | 1,4-benzothiazepines et composes associes avec des groupes cyclopropanol comme medicaments a cibles multiples |
Family Cites Families (27)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0368063B1 (fr) | 1988-11-05 | 1992-06-10 | Bayer Ag | Procédé pour la chlorination dans le noyau d'hydrocarbures aromatiques |
| GB9021813D0 (en) * | 1990-10-08 | 1990-11-21 | Ici Plc | Tricyclic heterocycles |
| CA2112360A1 (fr) | 1991-06-28 | 1993-12-23 | William Edward Bondinell | Antagonistes bicycliques du fibrinogene |
| BR9307387A (pt) * | 1992-11-09 | 1999-08-31 | Boots Co Plc | Agentes terapêuticos |
| FR2752017B1 (fr) | 1996-08-01 | 1998-10-16 | Hispano Suiza Sa | Inverseur de poussee de turboreacteur a portes formant ecopes |
| GB9914745D0 (en) | 1999-06-24 | 1999-08-25 | Knoll Ag | Therapeutic agents |
| US20040229781A1 (en) * | 2000-05-10 | 2004-11-18 | Marks Andrew Robert | Compounds and methods for treating and preventing exercise-induced cardiac arrhythmias |
| US8022058B2 (en) * | 2000-05-10 | 2011-09-20 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US7718644B2 (en) * | 2004-01-22 | 2010-05-18 | The Trustees Of Columbia University In The City Of New York | Anti-arrhythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) and uses thereof |
| US7879840B2 (en) * | 2005-08-25 | 2011-02-01 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| US20020183307A1 (en) | 2000-07-26 | 2002-12-05 | Tremont Samuel J. | Novel 1,4-benzothiazephine and 1,5-benzothiazepine compounds as inhibitors of apical sodium co-dependent bile acid transport and taurocholate uptake |
| CN101307046B (zh) | 2000-10-30 | 2012-08-15 | 詹森药业有限公司 | 三肽酶抑制剂 |
| US7544678B2 (en) * | 2002-11-05 | 2009-06-09 | The Trustees Of Columbia University In The City Of New York | Anti-arrythmic and heart failure drugs that target the leak in the ryanodine receptor (RyR2) |
| AU2004220548A1 (en) | 2003-03-07 | 2004-09-23 | The Trustees Of Columbia University, In The City Of New York | Type 1 ryanodine receptor-based methods |
| US20090292119A1 (en) * | 2003-10-07 | 2009-11-26 | The Trustees Of Columbia University In The City Of New York | Methods for synthesizing benzothiazepine compounds |
| WO2006101495A1 (fr) | 2005-03-23 | 2006-09-28 | Battelle Memorial Institute | Systeme d'identification par radio-frequence a fonction avancee |
| US7704990B2 (en) | 2005-08-25 | 2010-04-27 | The Trustees Of Columbia University In The City Of New York | Agents for preventing and treating disorders involving modulation of the RyR receptors |
| WO2007127145A2 (fr) | 2006-04-25 | 2007-11-08 | The Trustees Of Columbia University In The City Of New York | Procédés et compositions de traitement de l'arythmie cardiaque chez des animaux non humains |
| WO2008060332A2 (fr) | 2006-06-02 | 2008-05-22 | The Trustees Of Columbia University In The City Of New York | Méthodes pour traiter ou réduire la fatigue musculaire |
| WO2008021432A2 (fr) | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions et méthodes de traitement d'états affectant le système nerveux |
| WO2008021439A2 (fr) * | 2006-08-17 | 2008-02-21 | The Trustees Of Columbia University In The City Of New York | Compositions et méthodes de traitement de l'hypertrophie cardiaque |
| WO2008064264A2 (fr) | 2006-11-20 | 2008-05-29 | Armgo Pharma, Inc. | Procédés in vivo d'identification et de criblage de composés qui modulent la liaison de calstabine à un récepteur de ryanodine |
| ATE536348T1 (de) * | 2008-03-03 | 2011-12-15 | Armgo Pharma Inc | Verfahren zur herstellung von benzothiazepinen aus gamma-aminoalkylbenzolen |
| CN101891706B (zh) * | 2010-04-09 | 2013-05-29 | 复旦大学 | 3,4-二氢苯并[f][1,4]噻氮杂*类化合物或其盐及其药物用途 |
| WO2012019071A1 (fr) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Méthodes de traitement prophylactique et thérapeutique de la sarcopénie |
| WO2012019076A1 (fr) | 2010-08-06 | 2012-02-09 | The Trustees Of Columbia University In The City Of New York | Compositions et méthodes de traitement prophylactique ou thérapeutique d'une lésion d'ischémie/reperfusion cardiaque |
| WO2012037105A1 (fr) | 2010-09-14 | 2012-03-22 | The Trustees Of Columbia University In The City Of New York | Procédés de traitement, d'amélioration ou de prévention de troubles et de maladies neuronaux induits par le stress |
-
2012
- 2012-05-11 EP EP12167732.2A patent/EP2708535A1/fr not_active Withdrawn
-
2013
- 2013-04-09 JO JOP/2013/0090A patent/JO3070B1/ar active
- 2013-04-12 UY UY0001034742A patent/UY34742A/es not_active Application Discontinuation
- 2013-04-17 TW TW102113668A patent/TWI507399B/zh active
- 2013-04-17 CA CA2870599A patent/CA2870599C/fr active Active
- 2013-04-17 AU AU2013248313A patent/AU2013248313B2/en active Active
- 2013-04-17 RU RU2014145939A patent/RU2644350C2/ru not_active IP Right Cessation
- 2013-04-17 KR KR1020147032345A patent/KR101731459B1/ko active Active
- 2013-04-17 PE PE2014001612A patent/PE20142193A1/es active IP Right Grant
- 2013-04-17 PL PL13164051T patent/PL2653466T3/pl unknown
- 2013-04-17 MX MX2014012575A patent/MX350890B/es active IP Right Grant
- 2013-04-17 PT PT131640518T patent/PT2653466E/pt unknown
- 2013-04-17 JP JP2015506221A patent/JP5965542B2/ja active Active
- 2013-04-17 AR ARP130101246A patent/AR090712A1/es unknown
- 2013-04-17 DK DK13164051.8T patent/DK2653466T3/en active
- 2013-04-17 SA SA113340479A patent/SA113340479B1/ar unknown
- 2013-04-17 ME MEP-2014-147A patent/ME01969B/me unknown
- 2013-04-17 RS RS20140701A patent/RS53711B1/sr unknown
- 2013-04-17 CN CN201380030477.8A patent/CN104350045B/zh active Active
- 2013-04-17 ES ES13164051.8T patent/ES2529890T3/es active Active
- 2013-04-17 CU CUP2014000119A patent/CU24327B1/es unknown
- 2013-04-17 SG SG11201406404YA patent/SG11201406404YA/en unknown
- 2013-04-17 EA EA201401141A patent/EA027922B1/ru not_active IP Right Cessation
- 2013-04-17 AP AP2014008011A patent/AP3591A/xx active
- 2013-04-17 SI SI201330014T patent/SI2653466T1/sl unknown
- 2013-04-17 WO PCT/EP2013/057958 patent/WO2013156505A1/fr not_active Ceased
- 2013-04-17 MD MDA20140119A patent/MD4489C1/ro not_active IP Right Cessation
- 2013-04-17 GE GEAP201713636A patent/GEP20186836B/en unknown
- 2013-04-17 MY MYPI2014702980A patent/MY167783A/en unknown
- 2013-04-17 HU HUE13164051A patent/HUE024284T2/en unknown
- 2013-04-17 UA UAA201412301A patent/UA113759C2/uk unknown
- 2013-04-17 BR BR112014025670-5A patent/BR112014025670B1/pt active IP Right Grant
- 2013-04-17 EP EP20130164051 patent/EP2653466B1/fr active Active
- 2013-04-17 NZ NZ701122A patent/NZ701122A/en unknown
- 2013-04-18 US US13/865,359 patent/US20130281512A1/en not_active Abandoned
- 2013-11-11 US US14/076,474 patent/US8853198B2/en active Active
-
2014
- 2014-09-03 US US14/475,980 patent/US20140378437A1/en not_active Abandoned
- 2014-10-07 PH PH12014502256A patent/PH12014502256A1/en unknown
- 2014-10-07 IL IL235043A patent/IL235043A/en active IP Right Grant
- 2014-10-10 TN TN2014000424A patent/TN2014000424A1/fr unknown
- 2014-10-10 CO CO14224913A patent/CO7091184A2/es active IP Right Grant
- 2014-10-13 DO DO2014000230A patent/DOP2014000230A/es unknown
- 2014-10-14 CL CL2014002756A patent/CL2014002756A1/es unknown
- 2014-10-14 CR CR20140476A patent/CR20140476A/es unknown
- 2014-10-15 ZA ZA2014/07499A patent/ZA201407499B/en unknown
- 2014-10-17 GT GT201400222A patent/GT201400222A/es unknown
- 2014-10-30 NI NI201400123A patent/NI201400123A/es unknown
- 2014-11-13 MA MA37525A patent/MA37525B1/fr unknown
- 2014-11-17 EC ECIEPI201427564A patent/ECSP14027564A/es unknown
- 2014-11-18 HR HRP20141113TT patent/HRP20141113T8/hr unknown
- 2014-12-17 CY CY20141101052T patent/CY1115826T1/el unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MA37525B1 (fr) | Agents pour le traitement de troubles mettant en jeu la modulation de récepteurs de ryanodine | |
| MA40290A1 (fr) | Agents immunorégulateurs | |
| MA42397B1 (fr) | 4-azaindoles substituées et leur utilisation comme modulatoeurs de la récepteur glun2b | |
| MA51673B1 (fr) | Composés pour le traitement des troubles dépendants de kinases | |
| MA54231B1 (fr) | Composés de 2-formyl-3-hydroxyphényloxyméthyle capables de moduler l'hémoglobine | |
| MA34474B1 (fr) | Agonistes de gpr40 | |
| TN2009000324A1 (fr) | Composes tricycliques et leur utilisation comme modulateurs du recepteur de glucocorticoides | |
| MA31683B1 (fr) | Composes et procedes pour moduler fxr | |
| MA33334B1 (fr) | Derives de l-(piperidine-4-yl)-pyrazole servant de modulateurs de gpr 119 | |
| MA29785B1 (fr) | Agents permettant de prevenir et de traiter des troubles entrainant la modulation des recepteurs ryr | |
| MA29377B1 (fr) | Derives de la pyrimidine pour traitement de troubles a caractere hyperproliferatif | |
| MA37739B1 (fr) | Composés et compositions destinés à la modulation de l'activité de l'egfr | |
| MA33604B1 (fr) | Composés et compositions en tant qu'inhibiteurs de protéine kinase | |
| TN2014000420A1 (fr) | Derives d'indole et d'indazole qui activent la mpk | |
| EA200900831A1 (ru) | Модуляторы никотиновых ацетилхолиновых рецепторов | |
| MA34805B1 (fr) | Dérivés de 4-(5-cyano-pyrazole-1-yl)-pipéridine en tant que modulateurs du gpr119 | |
| MA33241B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| MA38076A1 (fr) | Dérivés d'oxazolidin-2-one-pyrimidine | |
| MX2021015500A (es) | Pirazolo-pirazinas sustituidas y su uso como moduladores del receptor glun2b. | |
| MA34968B1 (fr) | Urées asymétriques et utilisations médicales de celles-ci | |
| MA33190B1 (fr) | Composes pour le traitement de troubles metaboliques | |
| TN2016000040A1 (fr) | Inhibiteurs de porc2 et procedes pour leur utilisation | |
| MA35064B1 (fr) | Dérivés de thiéno[2,3-d]pyrimidine et leur utilisation pour traiter l'arythmie | |
| MA43250B1 (fr) | Composés d'oxadiazaspiro pour le traitement de l'abus et la dépendance aux drogues | |
| MX2022011310A (es) | Azabiciclo y derivados de diazepina para tratar trastornos oculares. |